Loading Curie Briefs...
Getting the latest healthcare news for you
Getting the latest healthcare news for you
A two-drug HIV combo (dolutegravir/lamivudine) matched a popular three-drug regimen in suppressing the virus, even in patients with very high viral loads. In a Spanish study, over 90% of ART-naive patients on either regimen achieved viral suppression by week 48. Safety profiles were also comparable, with no meaningful differences in CD4+ recovery, weight, or lipid changes.
For people newly starting HIV treatment with very high viral loads, a two-drug regimen may be just as effective as the standard three-drug approach. A retrospective study out of a tertiary hospital in Madrid found that dolutegravir/lamivudine (DTG/3TC) performed on par with bictegravir/emtricitabine/tenofovir alafenamide (BIC/FTC/TAF) at 48 weeks — even in patients with baseline viral loads exceeding 500,000 copies/mL.
The study included 40 ART-naive patients with HIV-1 RNA ≥ 500,000 copies/mL and CD4+ counts ≥ 200 cells/mm³. Both regimens showed strong and comparable virologic suppression, with no significant differences in CD4+ recovery, weight gain, or metabolic markers.
By the Numbers:
Why it matters: These findings challenge the assumption that two-drug regimens aren't suitable for patients with very high viral loads, potentially opening the door to simpler, better-tolerated treatment options for a broader group of people living with HIV.
